FDAble, LLC Publishes Safety Signal Analysis of Torisel®
FDAble, LLC Publishes Safety Signal Analysis of Torisel® Report examines adverse reactions reported for Torisel® with emphasis on infusion site extravasation and possible FDA regulatory actions. Glastonbury, CT (PRWEB) June 15, 2011 FDAble, LLC announced today the availability of its report, “Analysis of Torisel®: Adverse Events, Extravasation & Safety Signals.” The U.S. Food and Drug Administration (FDA) is currently evaluating the anti-cancer agent, Torisel® (temsirolimus), for 'Potential Signals of Serious Risks / New Safety Information...' using data collected
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Related Documents in PR Web
Categories
- Articles 309
- Bankruptcy 44
- Business 134
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 608
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4